SI-B003 + Izalontamab Brengitecan for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 Jul 2023: Trial registered, NCT05965856
  2. 11 Dec 2023: Trial started, NCT05965856

The trials

NCT05965856: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

State
Under way
Phase
Phase 2
People
52 planned
Started
11 Dec 2023
Primary completion
Dec 2026
Arms
BL-B01D1 + SI-B003
Results
None posted
  1. 28 Jul 2023: Trial registered
  2. 11 Dec 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.